Published in J Clin Oncol on June 29, 2009
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid Cancer | NCT02363647
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol (2010) 3.11
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid (2014) 2.77
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid (2015) 2.67
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res (2010) 2.44
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab (2010) 1.59
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. J Thyroid Res (2011) 1.46
2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J (2012) 1.45
Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist (2014) 1.43
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. PLoS One (2014) 1.43
Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol (2011) 1.19
Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches. Expert Opin Investig Drugs (2011) 1.18
Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab (2012) 1.13
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J Clin Endocrinol Metab (2013) 1.05
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab (2011) 1.00
Current understanding and management of medullary thyroid cancer. Oncologist (2013) 0.99
Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci (2013) 0.96
Thyroid cancer: molecular aspects and new therapeutic strategies. J Thyroid Res (2012) 0.94
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem Pharmacol (2014) 0.93
New targeted therapies for thyroid cancer. Curr Genomics (2011) 0.93
Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab (2011) 0.91
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther (2013) 0.88
Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer (2010) 0.88
Medical management of metastatic medullary thyroid cancer. Cancer (2014) 0.88
Thyroid cancer: emerging role for targeted therapies. Ther Adv Med Oncol (2010) 0.86
Improvement of radioimmunotherapy using pretargeting. Front Oncol (2013) 0.85
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab (2010) 0.85
Advances in thyroid cancer treatment: latest evidence and clinical potential. Ther Adv Med Oncol (2015) 0.84
Anti-angiogenic agents in Non-Small-Cell Lung Cancer (NSCLC): a perspective on the MONET1 (Motesanib NSCLC Efficacy and Tolerability) study. J Thorac Dis (2012) 0.84
Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol (2016) 0.84
Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) (2012) 0.83
Advanced medullary thyroid cancer: pathophysiology and management. Cancer Manag Res (2013) 0.83
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol (2013) 0.83
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab (2014) 0.83
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer. Clin Med Insights Oncol (2011) 0.82
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer (2012) 0.82
Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab (2014) 0.82
Activated RET and ROS: two new driver mutations in lung adenocarcinoma. Transl Lung Cancer Res (2013) 0.81
New treatment in advanced thyroid cancer. J Oncol (2012) 0.81
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol (2013) 0.81
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics (2014) 0.81
Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers. J Oncol (2010) 0.80
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer (2013) 0.80
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J Exp Clin Cancer Res (2010) 0.80
Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics (Sao Paulo) (2012) 0.80
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 0.79
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res (2010) 0.79
¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2014) 0.79
Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer. Onco Targets Ther (2011) 0.78
Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics (2012) 0.78
Personalization of targeted therapy in advanced thyroid cancer. Curr Genomics (2014) 0.77
Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res (2011) 0.77
Synthesis and in vivo evaluation of an (18)F-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography. Am J Nucl Med Mol Imaging (2013) 0.77
Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice. Oncol Lett (2014) 0.76
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol (2011) 0.76
Cabozantinib for progressive metastatic medullary thyroid cancer: a review. Ther Clin Risk Manag (2014) 0.75
A case report of motesanib-induced biliary sludge formation causing obstructive cholangitis with acute pancreatitis treated by endoscopic sphincterotomy. Medicine (Baltimore) (2016) 0.75
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology (2016) 0.75
Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget (2016) 0.75
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther (2016) 0.75
Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother (2012) 0.75
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol (2014) 0.75
Vandetanib. J Adv Pract Oncol (2012) 0.75
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications. J Clin Med Res (2016) 0.75
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase. J Mol Model (2015) 0.75
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab (2017) 0.75
Prognostic Impact of miR-224 and RAS Mutations in Medullary Thyroid Carcinoma. Int J Endocrinol (2017) 0.75
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases. Mol Diagn Ther (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol (2006) 6.57
High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol (2006) 5.86
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2008) 5.29
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2005) 4.96
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol (2012) 3.75
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol (2010) 3.15
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis (2004) 3.10
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol (2005) 2.98
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med (2012) 2.82
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab (2010) 2.74
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol (2008) 2.70
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62
Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood (2010) 2.60
Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet (2003) 2.54
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res (2010) 2.44
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol (2013) 2.43
A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid (2008) 2.41
FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics (2011) 2.37
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32
Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery (2012) 2.29
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci (2007) 2.07
Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients. J Clin Oncol (2005) 2.05
B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A (2010) 2.03
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther (2010) 1.94
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid (2005) 1.89
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Obesity and the risk of papillary thyroid cancer: a pooled analysis of three case-control studies. Thyroid (2014) 1.81
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res (2012) 1.80
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Major and minor salivary gland tumors. Crit Rev Oncol Hematol (2009) 1.77
Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid (2013) 1.77
Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol (2003) 1.77
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol (2011) 1.74
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.70
Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging (2003) 1.68
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg (2003) 1.64
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab (2010) 1.63
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology (2009) 1.62
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab (2011) 1.60
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery (2003) 1.60
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med (2003) 1.55
Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab (2007) 1.53
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab (2004) 1.52
Paraneoplastic glomerular diseases and malignancies. Crit Rev Oncol Hematol (2008) 1.52
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab (2010) 1.50
Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila) (2013) 1.50
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Maintenance chemotherapy in non-small cell lung cancer. J Natl Compr Canc Netw (2010) 1.48